To Evaluate the Efficacy and Safety of Shampoo TD03 and TD07 in Scalp Diseases

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Scalp Conditions are common chronic skin inflamations with the occurence rate of 1 - 5 % among the population. TD03 shampoo and TD07 shampoo are widely used to avoid hair loss with successful rate reaching nearly 95%. This trial is going to evaluate the efficacy of getting rid of dandruff as well as the safety of the investigational products in comparison to a reference (ketoconazole 2%) during a 4-week treatment period.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunstar Joint Stock Company
• Collaborator: Big Leap Clinical Research Support Joint Stock Company
• Treatments: Ketoconazole

Criteria

Inclusion Criteria:

• > 18 years old and signed the ICF.

• Diagnosed with head skin inflamtion with IGA <= 3.

• Voluntary sign the ICF before any procedures.

• No hypersentivity to the IP.

Exclusion Criteria:

• Use oral antifungal 1 month prior to the trial participation or topical antifungal 2 weeks prior to the trial participation.

• Suffering chronic or acute diseases that may affect the trial.